| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| S W Kim, S H Lee, J-S Paic. In vivo rat model to measure hypogastric nerve stimulation-induced seminal vesicle and vasal pressure responses simultaneously. International journal of impotence research. vol 16. issue 5. 2005-02-15. PMID:14973527. |
male sprague-dawley rats were grouped based on agent administered: serotonin, clomipramine, fluoxetine, sertraline, paroxetine, prazosin, terazosin, and tamsulosin. |
2005-02-15 |
2023-08-12 |
rat |
| S W Kim, S H Lee, J-S Paic. In vivo rat model to measure hypogastric nerve stimulation-induced seminal vesicle and vasal pressure responses simultaneously. International journal of impotence research. vol 16. issue 5. 2005-02-15. PMID:14973527. |
serotonergic agents resulted in concentration-dependent inhibition of the hns-induced seminal vesicle pressure increases (clomipramine>serotonin>fluoxetine>sertraline approximately paroxetine). |
2005-02-15 |
2023-08-12 |
rat |
| Martin A Javors, Chamindi Seneviratne, John D Roache, Nassima Ait-Daoud, Susan E Bergeson, M Consuelo Walss-Bass, Fatema Z Akhtar, Bankole A Johnso. Platelet serotonin uptake and paroxetine binding among allelic genotypes of the serotonin transporter in alcoholics. Progress in neuro-psychopharmacology & biological psychiatry. vol 29. issue 1. 2005-02-15. PMID:15610939. |
platelet serotonin uptake and paroxetine binding among allelic genotypes of the serotonin transporter in alcoholics. |
2005-02-15 |
2023-08-12 |
human |
| Martin A Javors, Chamindi Seneviratne, John D Roache, Nassima Ait-Daoud, Susan E Bergeson, M Consuelo Walss-Bass, Fatema Z Akhtar, Bankole A Johnso. Platelet serotonin uptake and paroxetine binding among allelic genotypes of the serotonin transporter in alcoholics. Progress in neuro-psychopharmacology & biological psychiatry. vol 29. issue 1. 2005-02-15. PMID:15610939. |
concentration curves of [3h]5-ht and [3h]paroxetine were used to quantify the equilibrium constant (km) and maximum 5-ht uptake rate (vmax) for 5-htt uptake into intact platelets and the dissociation constant (kd) and maximum specific binding density (bmax) for paroxetine binding to platelet membranes, respectively. |
2005-02-15 |
2023-08-12 |
human |
| Arata Horii, Kenji Mitani, Tadashi Kitahara, Atsuhiko Uno, Noriaki Takeda, Takeshi Kub. Paroxetine, a selective serotonin reuptake inhibitor, reduces depressive symptoms and subjective handicaps in patients with dizziness. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. vol 25. issue 4. 2005-02-10. PMID:15241233. |
paroxetine, a selective serotonin reuptake inhibitor, reduces depressive symptoms and subjective handicaps in patients with dizziness. |
2005-02-10 |
2023-08-12 |
Not clear |
| Arata Horii, Kenji Mitani, Tadashi Kitahara, Atsuhiko Uno, Noriaki Takeda, Takeshi Kub. Paroxetine, a selective serotonin reuptake inhibitor, reduces depressive symptoms and subjective handicaps in patients with dizziness. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. vol 25. issue 4. 2005-02-10. PMID:15241233. |
in this prospective study, we aimed to elucidate the role of paroxetine, a selective serotonin reuptake inhibitor, in the treatment of dizziness. |
2005-02-10 |
2023-08-12 |
Not clear |
| Richard C Shelton, Stephen M Stah. Risperidone and paroxetine given singly and in combination for bipolar depression. The Journal of clinical psychiatry. vol 65. issue 12. 2005-02-07. PMID:15641878. |
the current study was intended to evaluate the effects of the novel antipsychotic risperidone, the selective serotonin reup-take inhibitor (ssri) paroxetine, and the combination in patients with bipolar disorder. |
2005-02-07 |
2023-08-12 |
Not clear |
| Fenghua Chen, Mads Breum Larsen, Henrik Amtoft Neubauer, Connie Sánchez, Per Plenge, Ove Wibor. Characterization of an allosteric citalopram-binding site at the serotonin transporter. Journal of neurochemistry. vol 92. issue 1. 2005-02-02. PMID:15606893. |
dissociation of [3h]s-citalopram from sert is most potently inhibited by s-citalopram followed by r-citalopram, sertraline, serotonin and paroxetine. |
2005-02-02 |
2023-08-12 |
human |
| Peter H Silverston. Qualitative review of SNRIs in anxiety. The Journal of clinical psychiatry. vol 65 Suppl 17. 2005-02-01. PMID:15600378. |
many pharmacologic agents have been used to treat anxiety disorders, and among those in current use are newer benzodiazepines (alprazolam), azapirones (buspirone), selective serotonin reuptake inhibitors (paroxetine and sertraline), and venlafaxine, a serotonin-norepinephrine reuptake inhibitor (snri). |
2005-02-01 |
2023-08-12 |
Not clear |
| Nicole Kotzailias, Michael Marker, Bernd Jilm. Early effects of paroxetine on serotonin storage, plasma levels, and urinary excretion: a randomized, double-blind, placebo-controlled trial. Journal of clinical psychopharmacology. vol 24. issue 5. 2005-01-28. PMID:15349011. |
early effects of paroxetine on serotonin storage, plasma levels, and urinary excretion: a randomized, double-blind, placebo-controlled trial. |
2005-01-28 |
2023-08-12 |
human |
| Nicole Kotzailias, Michael Marker, Bernd Jilm. Early effects of paroxetine on serotonin storage, plasma levels, and urinary excretion: a randomized, double-blind, placebo-controlled trial. Journal of clinical psychopharmacology. vol 24. issue 5. 2005-01-28. PMID:15349011. |
twenty healthy male smoking volunteers received the selective serotonin reuptake inhibitors paroxetine 20 mg/d for 18 days in a double-blind, placebo-controlled, block-randomized, 2-way crossover study to characterize the acute effect of paroxetine on serotonin plasma levels and urinary excretion. |
2005-01-28 |
2023-08-12 |
human |
| Nicole Kotzailias, Michael Marker, Bernd Jilm. Early effects of paroxetine on serotonin storage, plasma levels, and urinary excretion: a randomized, double-blind, placebo-controlled trial. Journal of clinical psychopharmacology. vol 24. issue 5. 2005-01-28. PMID:15349011. |
paroxetine decreased intraplatelet serotonin concentrations by a median of 16% after 24 hours and by -93% after 18 days (p < 0.001). |
2005-01-28 |
2023-08-12 |
human |
| Nicole Kotzailias, Michael Marker, Bernd Jilm. Early effects of paroxetine on serotonin storage, plasma levels, and urinary excretion: a randomized, double-blind, placebo-controlled trial. Journal of clinical psychopharmacology. vol 24. issue 5. 2005-01-28. PMID:15349011. |
in conclusion, initiation of paroxetine treatment does not increase plasma concentrations of the potent vasoconstrictor serotonin to a pathologically relevant extent. |
2005-01-28 |
2023-08-12 |
human |
| Smriti Iyengar, Amy A Webster, Susan K Hemrick-Luecke, Jimmy Yu Xu, Rosa Maria A Simmon. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. The Journal of pharmacology and experimental therapeutics. vol 311. issue 2. 2005-01-25. PMID:15254142. |
the ability of duloxetine to antagonize 5-ht depletion in para-chloramphetamine-treated rats was comparable with that of paroxetine, a selective serotonin reuptake inhibitor (ssri), whereas its ability to antagonize ne depletion in alpha-methyl-m-tyrosine-treated rats was similar to norepinephrine reuptake inhibitors (nris), thionisoxetine or desipramine. |
2005-01-25 |
2023-08-12 |
human |
| D Jeffrey Newport, Michael J Owens, David L Knight, Kim Ragan, Neal Morgan, Charles B Nemeroff, Zachary N Stow. Alterations in platelet serotonin transporter binding in women with postpartum onset major depression. Journal of psychiatric research. vol 38. issue 5. 2005-01-24. PMID:15380396. |
in the present study, platelet serotonin transporter (sert) binding was assessed using [(3)h]paroxetine in 14 depressed pregnant women, 31 normal healthy pregnant women, 39 depressed postpartum women, and 27 normal healthy postpartum women; all of the subjects were drug-free. |
2005-01-24 |
2023-08-12 |
human |
| Denis J David, Nicolas Froger, Bruno Guiard, Cédric Przybylski, Gaelle Jego, Claudette Boni, Stephen P Hunt, Carmen De Felipe, Michel Hamon, Christian Jacquot, Alain M Gardier, Laurence Lanfume. Serotonin transporter in substance P (neurokinin 1) receptor knock-out mice. European journal of pharmacology. vol 492. issue 1. 2005-01-18. PMID:15145704. |
we recently demonstrated that mice lacking the gene for substance p (neurokinin 1) receptors (nk1-/-) show improved cortical dialysate serotonin (5-ht) responses to paroxetine [j. neurosci. |
2005-01-18 |
2023-08-12 |
mouse |
| Peng Wei, Glenn W Kaatz, Robert J Kern. Structural differences between paroxetine and femoxetine responsible for differential inhibition of Staphylococcus aureus efflux pumps. Bioorganic & medicinal chemistry letters. vol 14. issue 12. 2005-01-06. PMID:15149651. |
in this study the chemical modification of paroxetine was employed to determine which structural differences between the paroxetine-like and femoxetine-like selective serotonin reuptake inhibitors is responsible for the differential potency of these agents in the inhibition of staphylococcus aureus multidrug efflux pump systems. |
2005-01-06 |
2023-08-12 |
Not clear |
| Mark B Hamner, Sophie Robert, B Christopher Frue. Treatment-resistant posttraumatic stress disorder: strategies for intervention. CNS spectrums. vol 9. issue 10. 2005-01-04. PMID:15448585. |
the first-line medications for ptsd are antidepressants, with two selective serotonin reuptake inhibitors (sertraline and paroxetine) currently food and drug administration-indicated for ptsd. |
2005-01-04 |
2023-08-12 |
Not clear |
| Gabriele Mas. Pharmacotherapy of pervasive developmental disorders in children and adolescents. CNS drugs. vol 18. issue 14. 2004-12-29. PMID:15584771. |
pharmacological, efficacy and safety data on drugs acting on serotonin (serotonergic agents such as clomipramine, fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine), on both serotonin and norepinephrine (venlafaxine and mirtazapine), dopamine (dopamine-blocking antipsychotics such as haloperidol and pimozide), and on both serotonin and dopamine (atypical antipsychotics such as clozapine, risperidone, olanzapine, quetiapine and ziprasidone) are presented. |
2004-12-29 |
2023-08-12 |
Not clear |
| Kazufumi Hirano, Syuji Maruyama, Ryohei Kimura, Yoshiyuki Kagawa, Shizuo Yamad. In vivo identification and characterization of binding sites for selective serotonin reuptake inhibitors in mouse brain. Life sciences. vol 75. issue 24. 2004-12-14. PMID:15454344. |
the present study was undertaken to identify and characterize in vivo binding sites of selective serotonin reuptake inhibitors (ssris) in the mouse brain by using [3h]paroxetine as radioligand. |
2004-12-14 |
2023-08-12 |
mouse |